☆ 4.5 Article

MZF1 promotes tumour progression and resistance to anti-PD- L1 antibody treatment in hepatocellular carcinoma

JHEP REPORTS (2024)

Related references

Note: Only part of the references are listed.

Review Oncology

Immunotherapies for hepatocellular carcinoma

Josep M. Llovet et al.

Summary: Liver cancer, specifically hepatocellular carcinoma (HCC), is the second leading cause of cancer-related death globally. Traditional treatments involve specific drugs, but the emergence of immune checkpoint inhibitors has revolutionized the management of HCC.

NATURE REVIEWS CLINICAL ONCOLOGY (2022)

Add to Collection

Article Biochemistry & Molecular Biology

MZF1 mediates oncogene-induced senescence by promoting the transcription of p16INK4A

Dan Wu et al.

Summary: The study identified MZF1 as a transcriptional factor that recruits CHD7 to the p16(INK4A) promoter, mediating oncogenic ras-induced senescence in primary human cells. Reduced MZF1 expression in some cancers is associated with poor patient survival, suggesting MZF1 may act as a tumor suppressor.

ONCOGENE (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Differential Expression of PD-L1 during Cell Cycle Progression of Head and Neck Squamous Cell Carcinoma

Daniela Schulz et al.

Summary: The expression of PD-L1 by tumor cells is primarily associated with its immunosuppressive effect, but there is evidence of additional cell-intrinsic functions. PD-L1's function and expression vary depending on factors such as cell cycle, differentiation status, and microenvironment. Understanding these variations may provide insights into differential response to PD-1/PD-L1 antibody therapy and optimize antibody-based immunotherapy.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Add to Collection

Article Medicine, General & Internal

Hepatocellular carcinoma

Josep M. Llovet et al.

Summary: Liver cancer, particularly hepatocellular carcinoma (HCC), poses a significant global health challenge with rising incidence projected to exceed 1 million cases by 2025. Infection by hepatitis B and C viruses remains a major risk factor for HCC, while non-alcoholic steatohepatitis is emerging as a more common risk factor in Western countries. Advances in systemic therapies for HCC, including immunotherapies and targeted therapies, are expected to revolutionize the management of this disease.

NATURE REVIEWS DISEASE PRIMERS (2021)

Add to Collection

Article Cell Biology

Down-regulation of RCC1 sensitizes immunotherapy by up-regulating PD-L1 via p27kip1/CDK4 axis in non-small cell lung cancer

Xiaozhu Zeng et al.

Summary: High expression of regulator of chromosome condensation 1 (RCC1) is associated with poor prognosis in NSCLC. Knockdown of RCC1 inhibits proliferation of lung adenocarcinoma cells, increases PD-L1 expression, and decreases CDK4 expression. This study suggests that RCC1 up-regulates PD-L1 expression and decreasing resistance to ICIs, providing a new approach to enhance the efficacy of PD-L1 monoclonal antibody by targeting RCC1.

JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2021)

Add to Collection

Review Cell Biology

New Insights into CDK Regulators: Novel Opportunities for Cancer Therapy

Marina Bury et al.

Summary: Cyclins and CDKs regulate cell cycle transitions, controlled by CKIs. RPICs, a third group of CKIs, play a significant role in cellular senescence.

TRENDS IN CELL BIOLOGY (2021)

Add to Collection

Article Oncology

Hypoxic Glioma Stem Cell-Derived Exosomes Containing Linc01060 Promote Progression of Glioma by Regulating the MZE1/c-Myc/HIF1α Axis

Junjun Li et al.

Summary: The study elucidated the mechanisms by which hypoxic lncRNA derived from glioma stem cells (GSC) drive glioma progression, involving the Linc01060 gene, exosomes containing it, and proteins regulating the gene. Transfer of exosomes from GSCs to glioma cells increased Linc01060 levels and activated prooncogenic signaling pathways. Inhibition of Linc01060-containing exosomes or targeting the Linc01060/MZEI/c-Myc/HIF1 alpha axis could be an effective therapeutic strategy in glioma.

CANCER RESEARCH (2021)

Add to Collection

Review Immunology

Lactate modulation of immune responses in inflammatory versus tumour microenvironments

Michelangelo Certo et al.

Summary: The microenvironments of cancerous tissues and tissues affected by chronic inflammatory diseases exhibit different immune states but similar metabolic states. Understanding the metabolic signature allows for therapeutic intervention to reset metabolite availability and correct dysregulated immune states.

NATURE REVIEWS IMMUNOLOGY (2021)

Add to Collection

Review Cell Biology

Zinc Finger Transcription Factor MZF1-A Specific Regulator of Cancer Invasion

Ditte Marie Brix et al.

CELLS (2020)

Add to Collection

Article Medicine, General & Internal

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Richard S. Finn et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Medicine, Research & Experimental

Therapeutic targeting of YY1/MZF1 axis by MZF1-uPEP inhibits aerobic glycolysis and neuroblastoma progression

Erhu Fang et al.

THERANOSTICS (2020)

Add to Collection

Article Oncology

β-Catenin Activation Promotes Immune Escape and Resistance to Anti-PD-1 Therapy in Hepatocellular Carcinoma

Marina Ruiz de Galarreta et al.

CANCER DISCOVERY (2019)

Add to Collection

Article Oncology

Transcription Factor Myeloid Zinc-Finger 1 Suppresses Human Gastric Carcinogenesis by Interacting with Metallothionein 2A

Shuye Lin et al.

CLINICAL CANCER RESEARCH (2019)

Add to Collection

Article Biochemistry & Molecular Biology

Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF-κB Activation and PD-L1 Expression

Xin Jin et al.

MOLECULAR CELL (2019)

Add to Collection

Article Multidisciplinary Sciences

Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance

Jinfang Zhang et al.

NATURE (2018)

Add to Collection

Article Oncology

CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation

Jiehui Deng et al.

CANCER DISCOVERY (2018)

Add to Collection

Article Cell Biology

The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade

David A. Schaer et al.

CELL REPORTS (2018)

Add to Collection

Article Gastroenterology & Hepatology

Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma

Julien Bollard et al.

GUT (2017)

Add to Collection

Article Biochemistry & Molecular Biology

Role and Regulation of Myeloid Zinc Finger Protein 1 in Cancer

Taka Eguchi et al.

JOURNAL OF CELLULAR BIOCHEMISTRY (2015)

Add to Collection

Article Biochemistry & Molecular Biology

MIF4G domain containing protein regulates cell cycle and hepatic carcinogenesis by antagonizing CDK2-dependent p27 stability

C. Wan et al.

ONCOGENE (2015)

Add to Collection

Article Biochemistry & Molecular Biology

Osteopontin mediates an MZF1-TGF-β1-dependent transformation of mesenchymal stem cells into cancer-associated fibroblasts in breast cancer

C. E. Weber et al.

ONCOGENE (2015)

Add to Collection

Article Oncology

A Systematic Screen for CDK4/6 Substrates Links FOXM1 Phosphorylation to Senescence Suppression in Cancer Cells

Lars Anders et al.

CANCER CELL (2011)

Add to Collection

Article Cell Biology

Mzf1 controls cell proliferation and tumorigenesis

M Gaboli et al.

GENES & DEVELOPMENT (2001)

Add to Collection

© Peeref 2019-2024. All rights reserved.